Simultaneous delivery of cytotoxic and biologic therapeutics using nanophotoactivatable liposomes enhances treatment efficacy in a mouse model of pancreatic cancer

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 12, Issue 1, 2016, Pages 223-234

  Tangutoori, Shifalika ^a,c   Spring, Bryan Q ^a   Mai, Zhiming ^a   Palanisami, Akilan ^a   Mensah, Lawrence B ^a,d   Hasan, Tayyaba ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MIT DIVISION OF HEALTH SCIENCES AND TECHNOLOGY   (United States)

^c Nemucore Medical Innovations Inc   (United States)

^d MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

Avastin; Benzoporphyrin derivative; Bevacizumab; Combinatorial chemotherapy; Liposomes; Nanomedicine; Nanoparticle; Pancreatic cancer; Photodynamic therapy

Indexed keywords

ANTIBODIES; CHEMOTHERAPY; CHROMOPHORES; CYTOTOXICITY; DISEASES; ENZYME ACTIVITY; LIPID BILAYERS; LIPOSOMES; MAMMALS; MEDICAL NANOTECHNOLOGY; MONOCLONAL ANTIBODIES; NANOPARTICLES; TUMORS;

AVASTIN; BENZOPORPHYRIN-DERIVATIVE MONOACID; BEVACIZUMAB; MEDIATED SIGNALING PATHWAYS; MONOCLONAL ANTIBODIES (MAB); PANCREATIC CANCERS; PHOTODYNAMIC THERAPY (PDT); SPATIOTEMPORAL DELIVERIES;

PHOTODYNAMIC THERAPY;

BEVACIZUMAB; LIPOSOME; VASCULOTROPIN; VERTEPORFIN; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BIOLOGICAL PRODUCT; DELAYED RELEASE FORMULATION; NANOCAPSULE; PHOTOSENSITIZING AGENT; PORPHYRIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG RELEASE; DRUG STABILITY; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; LIPID BILAYER; MOUSE; NONHUMAN; PANCREAS ADENOCARCINOMA; PHOTOCYTOTOXICITY; PHOTODYNAMIC THERAPY; PHYSICAL CHEMISTRY; SHELF LIFE; SIGNAL TRANSDUCTION; ZETA POTENTIAL; ANIMAL; CHEMISTRY; DELAYED RELEASE FORMULATION; DRUG POTENTIATION; LIGHT; MULTIMODALITY CANCER THERAPY; NUDE MOUSE; PANCREATIC NEOPLASMS; PATHOLOGY; PHOTOCHEMOTHERAPY; PROCEDURES; RADIATION RESPONSE; ULTRASTRUCTURE;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; BEVACIZUMAB; BIOLOGICAL PRODUCTS; COMBINED MODALITY THERAPY; DELAYED-ACTION PREPARATIONS; DRUG SYNERGISM; LIGHT; MICE; MICE, NUDE; NANOCAPSULES; PANCREATIC NEOPLASMS; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PORPHYRINS;

EID: 84957057288     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2015.08.007     Document Type: Article

References (57)

1. Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015, 65:5-29.
2. SEER cancer statistics review, 1975-2006 2009, National Cancer Institute, Bethesda, MD, http://seer.cancer.gov/csr/1975_2006/, based on November 2008 SEER data submission, posted to the SEER web site. M.J. Horner, L.A.G. Ries, M. Krapcho, N. Neyman, R. Aminou, N. Howlader (Eds.).
3. Bardeesy N., DePinho R. Pancreatic cancer biology and genetics. Nat Rev Cancer 2002, 2:897-909.
4. Bardeesy N. Molecular signaling pathways in pancreatic cancer. Pancreatic cancer 2005, 43-70. Jones and Bartlett Publishers, Boston. 1st ed. D.D. Von Hoff, D.B. Evans, R.H. Hruban (Eds.).
5. Kessel D., Erickson C. Porphyrin photosensitization of multiresistant cell types. Photochem Photobiol 1992, 55:397-399.
6. Canti G., Lattuada D., Morelli S., Nicolin A., Cubeddu R., Taroni P., et al. Efficacy of photodynamic therapy against doxorubicin-resistant murine tumors. Cancer Lett 1995, 93:255-259.
7. Duska L.R., Hamblin M.R., Miller J.L., Hasan T. Combination photoimmunotherapy and cisplatin: effects on human ovarian cancer ex vivo. J Natl Cancer Inst 1999, 91:1557-1563.
8. Preise D., Mazor O., Koudinova N., Liscovitch M., Scherz A., Salomon Y. Bypass of tumor drug resistance by antivascular therapy. Neoplasia 2003, 5:475-480.
9. Holt J.J., Gannon M.K., Tombline G., McCarty T.A., Page P.M., Bright F.V., et al. A cationic chalcogenoxanthylium photosensitizer effective in vitro in chemosensitive and multidrug-resistant cells. Bioorg Med Chem 2006, 14:8635-8643.
10. Xie Q., Jia L., Liu Y.H., Wei C.G. Synergetic anticancer effect of combined gemcitabine and photodynamic therapy on pancreatic cancer in vivo. World J Gastroenterol 2009, 15:737-741.
11. Mikvy P., Messman H., MacRobert A.J., Pauer M., Sams V.R., Davies C.L., et al. Photodynamic therapy of a transplanted pancreatic cancer model using meta-tetrahydroxyphenylchlorin (mTHPC). Br J Cancer 1997, 96:713-718.
12. Hajri A., Coffy S., Vallat F., Evrard S., Marescaux J., Aprahamian M. Human pancreatic carcinoma cells are sensitive to photodynamic therapy in vitro and in vivo. Br J Surg 1999, 86:899-906.
13. Bown S.G., Rogowska A.Z., Whitelaw D.E., Lees W.R., Lovat L.B., Ripley P., et al. Photodynamic therapy for cancer of the pancreas. Gut 2002, 50:549-557.
14. Ayaru L., Bown S.G., Pereira S.P. Photodynamic therapy for pancreatic and biliary tract carcinoma. Int J Gastrointest Cancer 2005, 35:1-13.
15. Fan B.G., Andren-Sandberg A. Photodynamic therapy for pancreatic cancer. Pancreas 2007, 34:385-389.
16. Celli J.P., Solban N., Liang A., Pereira S.P., Hasan T. Verteporfin-based photodynamic therapy overcomes gemcitabine insensitivity in a panel of pancreatic cancer cell lines. Lasers Surg Med 2011, 43:565-574.
17. Huggett M.T., Jermyn M., Gillams A., Illing R., Mosse S., Novelli M., et al. Phase I/II study of verteporfin photodynamic therapy in locally advanced pancreatic cancer. Br J Cancer 2014, 110:1698-1704.
18. Gorski D.H., Beckett M.A., Jaskowiak N.T., Calvin D.P., Mauceri H.J., Salloum R.M., et al. Blockade of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res 1999, 59:3374-3378.
19. Abdollahi A., Lipson K.E., Han X., Krempien R., Trinh T., Weber K.J., et al. SU5416 and SU6668 attenuate the angiogenic effects of radiation-induced tumor cell growth factor production and amplify the direct anti-endothelial action of radiation in vitro. Cancer Res 2003, 63:3755-3763.
20. Tran J., Master Z., Yu J.L., Rak J., Dumont D.J., Kerbel R.S. A role for survivin in chemoresistance of endothelial cells mediated by VEGF. Proc Natl Acad Sci U S A 2002, 99:4349-4354.
21. Wild R., Dings R.P., Subramanian I., Ramakrishnan S. Carboplatin selectively induces the VEGF stress response in endothelial cells: potentiation of antitumor activity by combination treatment with antibody to VEGF. Int J Cancer 2004, 110:343-351.
22. Justinger C., Schluter C., Oliviera-Frick V., Kopp B., Rubie C., Schilling M.K. Increased growth factor expression after hepatic and pancreatic resection. Oncol Rep 2008, 20:1527-1531.
23. Kosharskyy B., Solban N., Chang S.K., Rizvi I., Chang Y., Hasan T. A mechanism-based combination therapy reduces local tumor growth and metastasis in an orthotopic model of prostate cancer. Cancer Res 2006, 66:10953-10958.
24. Chang S.K., Rizvi I., Solban N., Hasan T. In vivo optical molecular imaging of vascular endothelial growth factor for monitoring cancer treatment. Clin Cancer Res 2008, 14:4146-4153.
25. Chen B., Pogue B.W., Luna J.M., Hardman R.L., Hoopes P.J., Hasan T. Tumor vascular permeabilization by vascular-targeting photosensitization: effects, mechanism, and therapeutic implications. Clin Cancer Res 2006, 12:917-923.
26. Mallidi S., Watanabe K., Timerman D., Schoenfeld D., Hasan T. Prediction of tumor recurrence and therapy monitoring using ultrasound-guided photoacoustic imaging. Theranostics 2015, 5:289-301.
27. Ferrario A., von Tiehl K.F., Rucker N., Schwarz M.A., Gill P.S., Gomer C.J. Antiangiogenic treatment enhances photodynamic therapy responsiveness in a mouse mammary carcinoma. Cancer Res 2000, 60:4066-4069.
28. Gomer C.J., Ferrario A., Luna M., Rucker N., Wong S. Photodynamic therapy: combined modality approaches targeting the tumor microenvironment. Lasers Surg Med 2006, 38:516-521.
29. Solban N., Pål S.K., Alok S.K., Sung C.K., Hasan T. Mechanistic investigation and implications of photodynamic therapy induction of vascular endothelial growth factor in prostate cancer. Cancer Res 2006, 66:5633-5640.
30. Jiang F., Zhang X., Kalkanis S.N., Zhang Z., Yang H., Katakowski M., et al. Combination therapy with antiangiogenic treatment and photodynamic therapy for the nude mouse bearing U87 glioblastoma. Photochem Photobiol 2008, 84:128-137.
31. Allen T.M. Liposomes. Opportunities in drug delivery. Drugs 1997, 54(Suppl. 4):8-14.
32. Campbell R.B., Fukumura D., Brown E.B., Mazzola L.M., Izumi Y., Jain R.K., et al. Cationic charge determines the distribution of liposomes between the vascular and extravascular compartments of tumors. Cancer Res 2002, 62:6831-6836.
33. Drummond D.C., Meyer O., Hong K., Kirpotin D.B., Papahadjopoulos D. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev 1999, 51:691-743.
34. Sengupta S., Eavarone D., Capila I., Zhao G., Watson N., Kiziltepe T., et al. Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system. Nature 2005, 436:568-572.
35. Fu A., Tang R., Hardie J., Farkas M.E., Rotello V.M. Promises and pitfalls of intracellular delivery of proteins. Bioconjug Chem 2014, 25:1602-1608.
36. Crielaard B.J., van der Wal S., Le H.T., Bode A.T., Lammers T., Hennink W.E., et al. Liposomes as carriers for colchicine-derived prodrugs: vascular disrupting nanomedicines with tailorable drug release kinetics. Eur J Pharm Sci 2012, 45:429-435.
37. Campbell R.B., Balasubramanian S.V., Straubinger R.M. Influence of cationic lipids on the stability and membrane properties of paclitaxel-containing liposomes. J Pharm Sci 2001, 90:1091-1105.
38. Tangutoori S., Ohta A., Gatley S., Campbell R.B. Repurposing an erstwhile cancer drug: a quantitative and therapeutic evaluation of alternative nanosystems for the delivery of colchicine to solid tumors. J Cancer Sci Ther 2014, 6:236-246.
39. Loura L.M., Fernandes F., Fernandes A.C., Ramalho J.P. Effects of fluorescent probe NBD-PC on the structure, dynamics and phase transition of DPPC. A molecular dynamics and differential scanning calorimetry study. Biochim Biophys Acta 2008, 1778:491-501.
40. Denekamp J. The tumour microcirculation as a target in cancer therapy: a clearer perspective. Eur J Clin Invest 1999, 29:733-736.
41. Dokka S., Toledo D., Shi X., Castranova V., Rojanasakul Y. Oxygen radical-mediated pulmonary toxicity induced by some cationic liposomes. Pharm Res 2000, 17:521-525.
42. Filion M.C., Phillips N.C. Major limitations in the use of cationic liposomes for DNA delivery. Int J Pharm 1998, 120:159-170.
43. Lorgis V., Chauffert B., Gentil J., Ghiringhelli F. Influence of localization of primary tumor on effectiveness of 5-fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) in patients with metastatic pancreatic adenocarcinoma: a retrospective study. Anticancer Res 2012, 32:4125-4130.
44. Assaf E., Verlinde-Carvalho M., Delbaldo C., Grenier J., Sellam Z., Pouessel D., et al. 5-Fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with metastatic pancreatic adenocarcinoma. Oncology 2011, 80:301-306.
45. Francois E., Bennouna J., Chamorey E., Etienne-Grimaldi M.C., Renée N., Senellart H., et al. Phase I trial of gemcitabine combined with capecitabine and erlotinib in advanced pancreatic cancer: a clinical and pharmacological study. Chemotherapy 2012, 58:371-380.
46. Mattiucci G.C., Ippolito E., D'Agostino G.R., Alfieri S., Antinori A., Crucitti A., et al. Long-term analysis of gemcitabine-based chemoradiation after surgical resection for pancreatic adenocarcinoma. Ann Surg Oncol 2013, 20:423-429.
47. Hong D.S., Choe J.H., Naing A., Wheler J.J., Falchook G.S., Piha-Paul S., et al. A phase 1 study of gemcitabine combined with dasatinib in patients with advanced solid tumors. Invest New Drugs 2013, 31:918-926.
48. Brell J.M., Krishnamurthi S.S., Rath L., Bokar J.A., Savvides P., Gibbons J., et al. Phase I trial of sunitinib and gemcitabine in patients with advanced solid tumors. Cancer Chemother Pharmacol 2012, 70:547-553.
49. Sweeney C.J., Chiorean E.G., Verschraegen C.F., Lee F.C., Jones S., Royce M., et al. A phase I study of sunitinib plus capecitabine in patients with advanced solid tumors. J Clin Oncol 2010, 28:4513-4520.
50. Celli J.P., Spring B.Q., Rizvi I., Evans C.L., Samkoe K.S., Verma S., et al. Imaging and photodynamic therapy: mechanisms, monitoring, and optimization. Chem Rev 2010, 110:2795-2838.
51. Lindenmann J., Matzi V., Neuboeck N., Anegg U., Baumgartner E., Maier A., et al. Individualized, multimodal palliative treatment of inoperable esophageal cancer: clinical impact of photodynamic therapy resulting in prolonged survival. Lasers Surg Med 2012, 44:189-198.
52. Lee Y., Baron E.D. Photodynamic therapy: current evidence and applications in dermatology. Semin Cutan Med Surg 2011, 30:199-209.
53. Chowdhary R.K., Shariff I., Dolphin D. Drug release characteristics of lipid based benzoporphyrin derivative. J Pharm Sci 2003, 6:13-19.
54. Aveline B.M., Hasan T., Redmond R.W. The effects of aggregation, protein binding and cellular incorporation on the photophysical properties of benzoporphyrin derivative monoacid ring A (BPDMA). J Photochem Photobiol B 1995, 30:161-169.
55. Spring B.Q., Abu-Yousif A.O., Palanisami A., Rizvi I., Zheng X., Mai Z., et al. Selective treatment and monitoring of disseminated cancer micrometastases in vivo using dual-function, activatable immunoconjugates. Proc Natl Acad Sci U S A 2014, 111:E933-E942.
56. Rizvi I., Celli J.P., Evans C.L., Abu-Yousif A.O., Muzikansky A., Pogue B.W., et al. Synergistic enhancement of carboplatin efficacy with photodynamic therapy in a three-dimensional model for micrometastatic ovarian cancer. Cancer Res 2010, 70:9319-9328.
57. You W.K., Sennino B., Williamson C.W., Falcon B., Hashizume H., Yao L.C., et al. VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer. Cancer Res 2011, 71:4758-4768.